The global market for miRNA Sequencing and Assays was valued at US$379.0 Million in 2024 and is projected to reach US$763.1 Million by 2030, growing at a CAGR of 12.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Global miRNA Sequencing and Assays Market - Key Trends & Drivers Summarized
Why Is miRNA Sequencing Gaining Unprecedented Attention in Biomedical Research?
MicroRNA (miRNA) sequencing has emerged as a critical tool in understanding gene regulation and its implications in various diseases. With the rise in complex diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions, researchers are increasingly turning to miRNA profiling to identify biomarkers and therapeutic targets. The ability of miRNAs to regulate gene expression and play a role in cellular processes makes them invaluable in precision medicine. The growing investment in genomics and advancements in next-generation sequencing (NGS) technologies have further fueled the adoption of miRNA sequencing. Moreover, public and private initiatives to fund life sciences research are accelerating the development of cutting-edge miRNA assay technologies. The increasing interest in personalized medicine is also contributing to the demand, as miRNA sequencing provides the precision and specificity required to tailor treatments.How Are Technological Advancements Revolutionizing the miRNA Assays Market?
The miRNA assays market is undergoing a technological transformation, driven by innovations in sequencing platforms and bioinformatics tools. Advanced sequencing technologies, such as single-cell RNA sequencing, are enabling researchers to obtain more detailed insights into miRNA expression and its role in disease pathways. Additionally, the integration of artificial intelligence and machine learning in data analysis has simplified the interpretation of complex miRNA datasets, making the technology more accessible to researchers and clinicians. Innovations in assay kits, including higher sensitivity and specificity, have enhanced the reliability of miRNA detection. Furthermore, the development of multiplexed assays that can simultaneously analyze multiple miRNAs has significantly reduced the cost and time associated with large-scale studies. These advancements not only improve the overall efficiency of miRNA analysis but also broaden its applicability in diagnostics, drug discovery, and therapeutic development.What Role Do Healthcare Applications Play in Expanding the Market?
The application of miRNA sequencing in healthcare is a major driver of its market expansion. In oncology, for instance, miRNA profiling is being used to develop diagnostic tests that can detect cancer at an early stage, predict patient outcomes, and monitor disease progression. Similarly, in neurology, miRNAs are being investigated as biomarkers for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions. In addition to diagnostics, miRNA assays are gaining traction in therapeutics, with numerous clinical trials exploring their use in targeted treatments. The integration of miRNA sequencing in prenatal screening, infectious disease diagnostics, and immune response monitoring further demonstrates its versatility. The increasing prevalence of chronic diseases and the global focus on early detection and precision medicine are expected to sustain the demand for miRNA sequencing and assays in the healthcare sector.What Is Driving Growth in the miRNA Sequencing and Assays Market?
The growth in the miRNA sequencing and assays market is driven by several factors that underscore its pivotal role in advancing biomedical research and healthcare. The rising prevalence of cancer and chronic diseases has significantly increased the demand for miRNA-based diagnostics and therapeutics. Advancements in NGS technologies have made miRNA sequencing more accurate, cost-effective, and widely accessible, further fueling market adoption. The growing focus on personalized medicine and the increasing integration of miRNA profiling in drug discovery pipelines are also key contributors. Moreover, the expanding application of miRNAs in non-invasive liquid biopsies and their role in understanding disease mechanisms have boosted their relevance in modern medicine. Together, these drivers are propelling the miRNA sequencing and assays market toward robust growth, reshaping the landscape of genomic research and clinical practice.Scope of the Study
The report analyzes the miRNA Sequencing and Assays market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments:
Product & Service (miRNA Sequencing & Assay Products, miRNA Sequencing & Assay Services); Technology (Sequencing by Synthesis Technology, Sequencing by Oligonucleotide Ligation & Detection (SOLiD) Technology, Nanopore Sequencing Technology, Sanger Sequencing Technology, Single Molecule Real-time (SMRT) Sequencing Technology); Application (Cancer Application, Polyglutamine Diseases Application, Autoimmune Diseases Application, Schizophrenia Application, Other Applications); End-Use (Research & Academic Institutes End-Use, Pharma & Biotech Companies End-Use, Other End-Uses).Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the miRNA Sequencing & Assay Products segment, which is expected to reach US$603.5 Million by 2030 with a CAGR of a 11.9%. The miRNA Sequencing & Assay Services segment is also set to grow at 14.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $103.3 Million in 2024, and China, forecasted to grow at an impressive 16.5% CAGR to reach $159.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Abcam Plc, HTG Molecular Diagnostics, Inc., Illumina, Inc., Lexogen, Maravai Life Sciences and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global miRNA Sequencing and Assays Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global miRNA Sequencing and Assays Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global miRNA Sequencing and Assays Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 27 companies featured in this miRNA Sequencing and Assays market report include:
- Abcam Plc
- HTG Molecular Diagnostics, Inc.
- Illumina, Inc.
- Lexogen
- Maravai Life Sciences
- Meridian Bioscience, Inc.
- New England Biolabs, Inc.
- Norgen Biotek Corp.
- PerkinElmer, Inc.
- QIAGEN NV
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abcam Plc
- HTG Molecular Diagnostics, Inc.
- Illumina, Inc.
- Lexogen
- Maravai Life Sciences
- Meridian Bioscience, Inc.
- New England Biolabs, Inc.
- Norgen Biotek Corp.
- PerkinElmer, Inc.
- QIAGEN NV
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 465 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 379 Million |
| Forecasted Market Value ( USD | $ 763.1 Million |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
